Ryvu Therapeutics S.A.
RVU
Rank in Stocks
#19699
Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to... Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology. Their primary experimental drug, RVU120, functions as a CDK8 kinase inhibitor and shows promise for development across hematological malignancies and solid tumors. This compound is presently in a Phase 1b clinical study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Among their other assets is SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, which is currently undergoing a Phase 2 clinical trial for acute myeloid leukemia. Furthermore, Ryvu's earlier research pipeline explores candidates in areas such as kinases, cancer metabolism, synthetic lethality, and immuno-oncology. The company, established in 2007, is based in Krakรณw, Poland.
Share Price
$4.51
Last synced: 2026-11-13
Market Cap
$98.24M
Change (1 day)
1.30%
Change (1 year)
-29.98%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Ryvu Therapeutics S.A. (RVU)
Category
Healthcare
Operating Margin for Ryvu Therapeutics S.A. (RVU)
Operating Margin as of November 2026 TTM: -134.74%
According to Ryvu Therapeutics S.A.'s latest financial reports, its current operating margin (TTM) is -134.74%. At the end of 2025 the company had an operating margin of -196.22%.
Operating Margin history for Ryvu Therapeutics S.A. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -134.74% | -31.33% |
| 2025 | -196.22% | 25.30% |
| 2024 | -156.60% | -27.30% |
| 2023 | -215.42% | 6.59% |
| 2022 | -202.10% | -78.22% |
| 2021 | -927.76% | 300.62% |
| 2020 | -231.58% | 118.39% |
| 2019 | -106.04% | 501.47% |
| 2018 | -17.63% | -222.52% |
| 2017 | 14.39% | -671.03% |
| 2016 | -2.52% | -149.90% |
| 2015 | 5.05% | -72.34% |
| 2014 | 18.26% | -212.86% |
| 2013 | -16.18% | -75.67% |
| 2012 | -66.50% | -8.33% |
| 2011 | -72.54% | 116.47% |
| 2010 | -33.51% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -98.55% |
US
|
|
| 33.87% | -100.25% |
US
|
|
| -116.04% | -99.14% |
US
|
|
| 25.57% | -100.19% |
AU
|
|
| 31.23% | -100.23% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Ryvu Therapeutics S.A.'s operating margin
What is Ryvu Therapeutics S.A.'s operating margin?
Ryvu Therapeutics S.A.'s operating margin is -134.74%, as of Nov 2026.
What was Ryvu Therapeutics S.A.'s operating margin in 2025?
In 2025, Ryvu Therapeutics S.A.'s operating margin was -196.22%, compared with -156.60% in 2024.
How has Ryvu Therapeutics S.A.'s operating margin changed since 2020?
From 2020 to 2025, Ryvu Therapeutics S.A.'s operating margin was highest in 2024 (-156.60%) and lowest in 2021 (-927.76%).
How does Ryvu Therapeutics S.A.'s operating margin compare with similar companies?
Ryvu Therapeutics S.A.'s operating margin (-134.74%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.